Literature DB >> 17336656

Microbicide drug candidates to prevent HIV infection.

Jan Balzarini1, Lut Van Damme2.   

Abstract

25 years after the first HIV/AIDS cases emerged in 1981, the disease continues to spread worldwide, with about 15 000 new infections every day. Although highly active antiretroviral therapy (HAART) has greatly reduced the rate of HIV infection, and the spread of the epidemic, this effect has largely been seen in developed countries. More than 90% of HIV-infected people live in developing countries, most of whom do not have access to this treatment. The development of efficient, widely available, and low-cost microbicides (gels and creams can be applied topically before sex) to prevent sexually transmitted HIV infections should be given high priority. We review different categories of microbicide drugs and lead compounds, their mechanism of action, current status of development, and progress in phase III trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336656     DOI: 10.1016/S0140-6736(07)60202-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  76 in total

1.  Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Authors:  Martha Stefanidou; Carolina Herrera; Naomi Armanasco; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  The microbicide tenofovir does not inhibit nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine samples.

Authors:  Billie Jo Wood; Patricia Rizzo-Price; Jeff Holden; Andrew Hardick; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

Review 4.  Rational design of novel HIV-1 entry inhibitors by RANTES engineering.

Authors:  Luca Vangelista; Massimiliano Secchi; Paolo Lusso
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

Review 5.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

6.  Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Cali Nguyen; Kathleen L Vincent; Massoud Motamedi; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

Review 7.  Vaginal drug distribution modeling.

Authors:  David F Katz; Andrew Yuan; Yajing Gao
Journal:  Adv Drug Deliv Rev       Date:  2015-04-28       Impact factor: 15.470

8.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

Review 9.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

10.  A lectin isolated from bananas is a potent inhibitor of HIV replication.

Authors:  Michael D Swanson; Harry C Winter; Irwin J Goldstein; David M Markovitz
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.